10-Q: Myriad Genetics Q1 2026 Earnings: Revenue Up, Net Loss Widens

Myriad Genetics reported a 2.3% increase in revenue for the first quarter of 2026, reaching $200.4 million, but experienced a significant widening of its net loss to $34.1 million.

Summary

• Total revenue for the three months ended March 31, 2026, was $200.4 million, an increase of $4.5 million (2.3%) compared to $195.9 million in the same period of 2025.
• Net loss for the quarter was $34.1 million, a substantial increase from a net loss of $0.1 million in the prior year's quarter.
• The company recorded a goodwill and long-lived asset impairment charge of $5.4 million in the current quarter, primarily related to its Women's Health reporting unit.
• Cash and cash equivalents decreased to $124.4 million as of March 31, 2026, from $149.6 million as of December 31, 2025.
• The company ended the quarter with $337.4 million in total stockholders' equity, down from $368.0 million at the end of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss despite modest revenue growth, coupled with an impairment charge.

Positives

• Total revenue increased by 2.3% to $200.4 million for the first quarter of 2026.
• Cancer Care Continuum revenue grew by $4.6 million to $120.2 million, driven by a 13% increase in volume.
• Mental Health revenue increased by $7.3 million to $38.3 million, due to a 15% increase in revenue per test and a 7% increase in volume.
• Sales and marketing expenses as a percentage of total revenue decreased to 36.7% from 35.3% in the prior year.
• General and administrative expenses decreased by $4.3 million, improving as a percentage of total revenue to 31.0% from 33.9%.

Negatives

• Net loss widened significantly to $34.1 million for the quarter, compared to a net loss of $0.1 million in the prior year.
• Prenatal Health revenue decreased by $7.4 million to $41.9 million, due to a 12% decrease in volume and a 4% decrease in revenue per test.
• Interest expense increased significantly due to the new term loan, contributing to a higher net loss.
• Goodwill and long-lived asset impairment charges of $5.4 million were recorded in the current quarter.
• Cash and cash equivalents decreased by $25.2 million during the quarter.

Risks

• Risk of sales and profit margins of existing tests declining.
• Risk of not being able to operate the business profitably.
• Risks related to achieving certain revenue growth targets and generating sufficient revenue from existing or new tests.
• Risks related to changes in senior management and successful implementation of the strategic plan.
• Risks related to changes in governmental or private insurers' coverage and reimbursement levels for tests.
• Risks related to increased competition and the development of new competing tests.
• Risk of not being able to develop or achieve commercial success for additional tests in a timely manner.
• Risk of not successfully developing new markets or channels for tests.
• Risk of termination or failure to maintain satisfactory terms for licenses to test technology.
• Risks related to delays or problems with operating laboratory testing facilities.
• Risks related to public concern over genetic testing.
• Risks related to regulatory requirements or enforcement and changes in healthcare payment systems.
• Risk of not being able to obtain new corporate partnerships, collaborations, or licenses, or acquire or develop new technologies or businesses on satisfactory terms.
• Risk of not successfully integrating and deriving benefits from licensed, acquired, or developed technologies or businesses.
• Risk of not securing additional financing if needed, in a timely manner or on favorable terms.
• Risks related to projections or estimates about the potential market opportunity for current and future products.
• Risk of not being able to protect proprietary technologies or that third parties may infringe upon them.
• Risk of patent-infringement claims or challenges to patent validity.
• Risks related to changes in intellectual property laws covering tests, patents, or enforcement.
• Risks related to security breaches, loss of data, and other disruptions, including from cyberattacks.
• Risks of new, changing, and competitive technologies and the inability to keep pace or leverage new technologies.
• Risk of not being able to comply with financial or operating covenants under credit or lending agreements.
• Risk of not being able to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Risks related to current and future investigations, claims, or lawsuits, including derivative claims, product or professional liability claims.
• Risks related to insurance coverage limits and scope of insurance coverage.
• Potential for future impairment charges if reporting unit fair values fall below carrying values.

Future Outlook

The company believes there are significant growth opportunities in addressing pressing healthcare needs through innovative molecular diagnostic testing and precision medicine solutions. Their long-term growth strategy focuses on leveraging differentiated strengths, including reputation, commercial reach, investments in science and innovation, technology-enabled operations, enhanced customer experience, strong commercial execution, and scalable operations. The strategic intent is to accelerate profitable growth by focusing on providing a comprehensive testing menu for the Cancer Care Continuum, growing Prenatal Health and Mental Health revenues at or above market growth, and delivering sustained profitable growth through financial and operational discipline. They plan to expand adoption of their testing portfolio and integrate precision medicine solutions more deeply into clinical workflows.

Management Comments

• The company believes there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
• Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine.
• Our strategy also leverages investments in science and innovation, technology-enabled operations, an enhanced customer experience, strong commercial execution, and scalable operations.
• Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model.
• We are committed to making molecular testing accessible and actionable for patients and providers while driving long-term growth and profitability.

Industry Context

StockSavvy.ai notes that Myriad Genetics' Q1 2026 results reflect ongoing shifts within the molecular diagnostics and precision medicine sector. The reported revenue growth, particularly in Cancer Care Continuum and Mental Health, aligns with broader industry trends of increasing adoption of genetic testing for disease risk assessment and treatment guidance. However, the decline in Prenatal Health revenue and the significant net loss highlight the competitive pressures and reimbursement challenges common across the industry.

Comparison to Industry Standards

• The revenue growth of 2.3% for the quarter is modest compared to some high-growth biotech and diagnostics companies, but may be in line with more established players in the specialized diagnostics market.
• The net loss of $34.1 million is a significant concern and indicates that the company is not yet achieving profitability, a common challenge for companies investing heavily in R&D and commercialization in the life sciences sector.
• The goodwill impairment charge of $5.4 million suggests that past acquisitions or investments may not have performed as expected, a risk that is present across the industry when companies pursue inorganic growth strategies.
• The company's focus on specific areas like Cancer Care Continuum, Prenatal Health, and Mental Health reflects a common strategy of specialization within the broader diagnostics market, aiming to capture market share in key therapeutic areas.

Legal Proceedings

• The company is involved in various disputes, claims, and legal actions, including class actions and other litigation, arising in the ordinary course of business, which could involve claims for substantial compensatory and punitive damages or indeterminate amounts of damages.
• The company is also involved in investigations by governmental agencies which may result in adverse judgments, settlements, fines, penalties, injunctions, or other relief.
• Qui Tam Lawsuit: In June 2023, the company received a civil investigative demand from the U.S. Department of Justice concerning alleged remuneration to physicians for referrals. A qui tam complaint was unsealed in January 2025, alleging violations of the False Claims Act. The government declined to intervene but later elected to intervene for the limited purpose of defending the constitutionality of the qui tam provisions.
• The company has not recorded any material accrual for loss contingencies as of March 31, 2026, but an unfavorable resolution could be material to financial condition, results of operations, or cash flows.
• Recoupment requests from third-party payors for alleged overpayments are received from time to time.

Stakeholder Impact

• Shareholders: The widening net loss and goodwill impairment may negatively impact shareholder value and confidence.
• Employees: Stock-based compensation continues to be a significant expense. The company's financial performance could affect future compensation and job security.
• Customers (Healthcare Providers/Patients): Continued focus on improving patient care, earlier detection, and lowering healthcare costs through molecular insights.
• Creditors: The company is in compliance with its credit facility covenants, indicating stability for lenders in the short term.

Next Steps

• Continue to focus on providing a comprehensive testing menu for the Cancer Care Continuum market.
• Grow Prenatal Health and Mental Health revenues at or above market growth.
• Deliver sustained profitable growth through financial and operational discipline.
• Leverage strong scientific foundation, deep clinical partnerships, and technology-enabled capabilities to expand adoption of testing portfolio.
• Integrate precision medicine solutions more deeply into clinical workflows.
• Present new Precise MRD data at the Society of Gynecologic Oncology (SGO) Annual Meeting.
• Expand access to MyChoice test to prostate cancer patients in Japan.
• Seek stockholder approval for the 2026 Employee, Director and Consultant Equity Incentive Plan and the amendment to the Amended and Restated 2012 Purchase Plan at the 2026 Annual Meeting.
• Continue to monitor reporting units for any triggering events or signs of impairment.

Key Dates

Recommendation

While revenue growth is present, the significant increase in net loss and the goodwill impairment charge are concerning. The company's strategy for future growth is outlined, but execution and a return to profitability are key concerns. The current financial performance warrants a 'hold' recommendation pending clearer signs of improved profitability and sustained revenue growth across all segments.

Keywords

Myriad Genetics, Form 10-Q, Quarterly Report, Molecular Diagnostics, Precision Medicine, Cancer Care Continuum, Prenatal Health, Mental Health, Revenue, Net Loss, Goodwill Impairment, Financial Statements, SEC Filing